APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: A post hoc subgroup analysis of the Phase III randomized MAGIC trial
Cancer Management and Research Aug 21, 2017
Schnadig ID, et al. – For the prevention of chemotherapy-induced nausea and vomiting (CINV) due to anthracycline plus, this study planned to examine the efficacy of APF530 versus ondansetron, each in a guideline–recommended three–drug regimen. In patients receiving anthracycline plus cyclophosphamide (AC)–based highly emetogenic chemotherapy (HEC), APF530 plus fosaprepitant and dexamethasone effectively prevented CINV.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
